NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD
327.32
+1.21 (+0.37%)
The current stock price of MEDP is 327.32 USD. In the past month the price decreased by -6.49%. In the past year, price decreased by -19.03%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.2 | 202.33B | ||
DHR | DANAHER CORP | 27.74 | 149.40B | ||
A | AGILENT TECHNOLOGIES INC | 24.09 | 36.49B | ||
IQV | IQVIA HOLDINGS INC | 16.95 | 33.25B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 30.92 | 26.63B | ||
WAT | WATERS CORP | 31.79 | 22.41B | ||
WST | WEST PHARMACEUTICAL SERVICES | 34.42 | 16.83B | ||
ICLR | ICON PLC | 13.57 | 15.69B | ||
ILMN | ILLUMINA INC | 36.22 | 14.07B | ||
RVTY | REVVITY INC | 22.89 | 13.65B | ||
AVTR | AVANTOR INC | 16.7 | 11.37B | ||
TECH | BIO-TECHNE CORP | 34.12 | 9.76B |
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,900 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
MEDPACE HOLDINGS INC
5375 Medpace Way
Cincinnati OHIO 45227 US
CEO: August J. Troendle
Employees: 5800
Company Website: https://investor.medpace.com/
Investor Relations: https://investor.medpace.com/
Phone: 15135799911
The current stock price of MEDP is 327.32 USD. The price increased by 0.37% in the last trading session.
The exchange symbol of MEDPACE HOLDINGS INC is MEDP and it is listed on the Nasdaq exchange.
MEDP stock is listed on the Nasdaq exchange.
16 analysts have analysed MEDP and the average price target is 355.11 USD. This implies a price increase of 8.49% is expected in the next year compared to the current price of 327.32. Check the MEDPACE HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MEDPACE HOLDINGS INC (MEDP) has a market capitalization of 9.97B USD. This makes MEDP a Mid Cap stock.
MEDPACE HOLDINGS INC (MEDP) currently has 5800 employees.
MEDPACE HOLDINGS INC (MEDP) has a support level at 310.62 and a resistance level at 334.1. Check the full technical report for a detailed analysis of MEDP support and resistance levels.
The Revenue of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 2.79% in the next year. Check the estimates tab for more information on the MEDP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MEDP does not pay a dividend.
MEDPACE HOLDINGS INC (MEDP) will report earnings on 2025-04-21, after the market close.
The PE ratio for MEDPACE HOLDINGS INC (MEDP) is 25.92. This is based on the reported non-GAAP earnings per share of 12.63 and the current share price of 327.32 USD. Check the full fundamental report for a full analysis of the valuation metrics for MEDP.
The outstanding short interest for MEDPACE HOLDINGS INC (MEDP) is 4.48% of its float. Check the ownership tab for more information on the MEDP short interest.
ChartMill assigns a fundamental rating of 7 / 10 to MEDP. MEDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months MEDP reported a non-GAAP Earnings per Share(EPS) of 12.63. The EPS increased by 42.23% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 19.17% | ||
ROA | 19.25% | ||
ROE | 48.98% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 75% to MEDP. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -0.09% and a revenue growth 2.79% for MEDP